FORTUNE -- For years, AngelList has freely facilitated introductions between entrepreneurs and investors. Now it's raised some big cash of its own.
Fortune has learned that AngelList recently raised around $24 million at a valuation in the $150 million range. Atlas Venture and Google Ventures helped lead the round, which included participation by more than 100 other institutions and individuals. Among the more notable names are Kleiner Perkins Caufield & Byers, Draper Fisher Jurvetson, Marc Andreessen, Max Levchin and Ev Williams (all of whom have profiles on the site).
None of the venture investors will receive a seat on the AngelList board of directors, nor are the equity investments tied to any proprietary insights. In fact, one reason the company raised money from so many different sources was so as not to appear beholden to any particular firm or individual.
Related: Venture capital gets disrupted
This is not the first time that AngelList has raised funding -- Atlas Venture, for example, first invested a small amount three years ago -- but this is the deal that could help transform AngelList from a popular project into one of Silicon Valley's top power players.
"I first invested personally when it was just [startup investment advice blog] VentureHacks, which was not a VC-backable business," explains Jeff Fagnan, a partner with Atlas Venture. "But today I'd compare it to Craigslist for startups, and they are doing a lot of the things that LinkedIn (LNKD) and NASDAQ (NDAQ) do for larger businesses."
Related: The future of startup 'demo days'
AngelList originally launched as a way to help connect entrepreneurs and investors, but since has expanded into such areas as recruiting and direct online investment (a lot of the $24 million was raised via the AngelList system).
It also has a program called "syndicates" -- a digital twist on the fundless sponsor model. From the AngelList site:
Here's an example. Sara decides to invest in a startup and asks for a $250k allocation in the company. She personally takes $50K of the allocation and decides to syndicate the rest. She shares the deal with investors and specifies that she is charging a 20% carry on the remaining $200K of her allocation. Sara's capital and her co-investor's capital is pooled into a $250K fund which invests in the startup.
In such a scenario, Sara would pay a small cut of her carry back to AngelList. Venture capitalist Hunter Walk yesterday blogged more about syndicates, giving three examples of their "powerful future."
AngelList declined to comment for this story, but I would assume that new products could be rolling out as soon as tomorrow -- as the decades-old ban on general solicitation is officially lifted by the SEC. For example, it will no longer be illegal for startups to tell a general audience that they are seeking investment (even though only accredited investors would be allowed to actually invest). The same will be true for private investment funds.
Sign up for my daily email newsletter on deals and deal-makers: GetTermSheet.com
Objective Logistics raises $5.3 million to grow its waitstaff management platform.
FORTUNE -- If you've ever worked in a bar or restaurant, you know that there are certain shifts and sections that are more desirable than others. And you also know that getting a good schedule is capricious at best, and at worst based on how much managerial butt you can kiss.
But Philip Beauregard is working to upend that dynamic through Objective MOREDan Primack - Jul 18, 2013 12:07 PM ET
Boston-area VC firm rebounds with new fund.
FORTUNE -- The first time I ever spoke with venture capitalist Jeff Fagnan was January 2009. I had heard that his firm, Atlas Venture, was cutting back on staff after finishing up fundraising more than $100 million below its $400 million target (and an even farther cry from the $750 million it had raised in the dotcom heyday). Not too enjoyable of a conversation. MOREDan Primack - May 1, 2013 10:28 AM ET
Tips for navigating early-stage investments in biotech.
By Bruce Booth, contributor
Venture capital is often called an apprenticeship business because experience matters and takes time to accumulate. But successful firms are able to translate and transfer experiential wisdom through institutional memory, which involves codifying what works and what doesn't. Back in 2007, we did this with our life science team by pulling together a detailed list of "Lessons Learned" from our existing MOREFeb 12, 2013 12:55 PM ET
A significant development for Boston's venture capital market.
Boston-area venture capitalist Ryan Moore has agreed to join Atlas Venture as a partner, Fortune has learned. He had spent the past 12 years with GrandBanks Capital, where his deals have included Enpocket (sold to Nokia), GlassHouse Technologies (in registration for an IPO) and Vivox.
This is a significant move for a number of reasons. So I'm going to list them in no particular MOREDan Primack - Sep 13, 2011 9:21 AM ET
New research on the VC industry turns conventional wisdom on its head.
In the world of venture capital, tech is the movie star and life sciences the second banana. The champion and the also-ran. Just look at the most recent Forbes Midas List, in which the first life sciences investor doesn't appear until #16 (Bryan Roberts of Venrock).
But new research suggests that this hierarchy has quietly reversed itself over the past MOREDan Primack - Jul 11, 2011 9:19 AM ET
|The medical marijuana ad that never aired, despite contrary media headlines|
|2 million students missing out on college aid|
|GM raising Corvette prices|
|China to fight pollution with drones|
|Boeing reports wing cracks on Dreamliners|